BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug will be used in Peptide Receptor Radionuclide Therapy (PRRT), which is a form of targeted treatment. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for adult patients with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors.
Click here to read the FDA press release about the approval: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm
Click here to read the Advanced Accelerator Applications press release about the approval: http://www.adacap.com/wp-content/uploads/2018/02/AAA-Lutathera-FDA-Approval-PR_2018-01-26-FINAL-2.pdf
The approval of LUTATHERA® is based on results from the NETTER-1 clinical study. Click here to read the article in the New England Journal of Medicine about the NETTER-1 study: http://www.nejm.org/doi/full/10.1056/NEJMoa1607427?query=featured_home&
Click here to read more about PRRT from the Society of Nuclear Medicine and Molecular Imaging: http://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=5691.
- What is peptide receptor radionuclide therapy (PRRT) and how does it work?
- What conditions are treated with PRRT?
- How is PRRT performed?
- What are the advantages of PRRT?
- Is PRRT safe?
- Side effects
- Home care
- Is PRRT covered by insurance?
- What’s new in PRRT research and development?